259 related articles for article (PubMed ID: 32845866)
1. Role of urinary NGAL and KIM-1 as biomarkers of early kidney injury in obese prepubertal children.
Polidori N; Giannini C; Salvatore R; Pelliccia P; Parisi A; Chiarelli F; Mohn A
J Pediatr Endocrinol Metab; 2020 Sep; 33(9):1183-1189. PubMed ID: 32845866
[TBL] [Abstract][Full Text] [Related]
2. Assessment of renal function in obese and overweight children with NGAL and KIM-1 biomarkers.
Gul A; Yilmaz R; Ozmen ZC; Gumuser R; Demir O; Unsal V
Nutr Hosp; 2020 Jul; 34(3):436-442. PubMed ID: 32207310
[TBL] [Abstract][Full Text] [Related]
3. Are there any new reliable markers to detect renal injury in obese children?
Bostan Gayret Ö; Taşdemir M; Erol M; Tekin Nacaroğlu H; Zengi O; Yiğit Ö
Ren Fail; 2018 Nov; 40(1):416-422. PubMed ID: 30035656
[TBL] [Abstract][Full Text] [Related]
4. Urinary NGAL is a Potential Biomarker for Early Renal Injury in Insulin Resistant Obese Non-diabetic Children.
Şen S; Özalp Kızılay D; Taneli F; Özen Ç; Ertan P; Özunan İ; Yıldız R; Ersoy B
J Clin Res Pediatr Endocrinol; 2021 Nov; 13(4):400-407. PubMed ID: 34013756
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of urinary neutrophil gelatinase-associated lipocalin and urinary kidney injury molecule-1 as biomarkers of renal function in cancer patients treated with cisplatin.
Ghadrdan E; Ebrahimpour S; Sadighi S; Chaibakhsh S; Jahangard-Rafsanjani Z
J Oncol Pharm Pract; 2020 Oct; 26(7):1643-1649. PubMed ID: 32046578
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in neonates receiving potential nephrotoxic drugs.
Sridharan K; Al Jufairi M; Al Segai O; Al Ansari E; Hashem Ahmed H; Husain Shaban G; Malalla Z; Al Marzooq R; Al Madhoob A; Saeed Tabbara K
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7078-7088. PubMed ID: 34859872
[TBL] [Abstract][Full Text] [Related]
7. Urine NGAL and KIM-1: tubular injury markers in acute lymphoblastic leukemia survivors.
Latoch E; Konończuk K; Taranta-Janusz K; Muszyńska-Rosłan K; Szymczak E; Wasilewska A; Krawczuk-Rybak M
Cancer Chemother Pharmacol; 2020 Dec; 86(6):741-749. PubMed ID: 33052454
[TBL] [Abstract][Full Text] [Related]
8. Urinary calprotectin, kidney injury molecule-1, and neutrophil gelatinase-associated lipocalin for the prediction of adverse outcome in pediatric acute kidney injury.
Westhoff JH; Seibert FS; Waldherr S; Bauer F; Tönshoff B; Fichtner A; Westhoff TH
Eur J Pediatr; 2017 Jun; 176(6):745-755. PubMed ID: 28409285
[TBL] [Abstract][Full Text] [Related]
9. Serially assessed bisphenol A and phthalate exposure and association with kidney function in children with chronic kidney disease in the US and Canada: A longitudinal cohort study.
Jacobson MH; Wu Y; Liu M; Attina TM; Naidu M; Karthikraj R; Kannan K; Warady BA; Furth S; Vento S; Trachtman H; Trasande L
PLoS Med; 2020 Oct; 17(10):e1003384. PubMed ID: 33052911
[TBL] [Abstract][Full Text] [Related]
10. Performance of urinary kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and N-acetyl-β-D-glucosaminidase to predict chronic kidney disease progression and adverse outcomes.
Lobato GR; Lobato MR; Thomé FS; Veronese FV
Braz J Med Biol Res; 2017 Mar; 50(5):e6106. PubMed ID: 28380198
[TBL] [Abstract][Full Text] [Related]
11. High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy.
Peters HP; Waanders F; Meijer E; van den Brand J; Steenbergen EJ; van Goor H; Wetzels JF
Nephrol Dial Transplant; 2011 Nov; 26(11):3581-8. PubMed ID: 21467131
[TBL] [Abstract][Full Text] [Related]
12. NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction.
Holzscheiter L; Beck C; Rutz S; Manuilova E; Domke I; Guder WG; Hofmann W
Clin Chem Lab Med; 2014 Apr; 52(4):537-46. PubMed ID: 24243749
[TBL] [Abstract][Full Text] [Related]
13. Urinary biomarkers in the early detection and follow-up of tubular injury in childhood urolithiasis.
Taşdemir M; Fuçucuoğlu D; Küçük SH; Erol M; Yiğit Ö; Bilge I
Clin Exp Nephrol; 2018 Feb; 22(1):133-141. PubMed ID: 28653226
[TBL] [Abstract][Full Text] [Related]
14. Determination of early urinary renal injury markers in obese children.
Goknar N; Oktem F; Ozgen IT; Torun E; Kuçukkoc M; Demir AD; Cesur Y
Pediatr Nephrol; 2015 Jan; 30(1):139-44. PubMed ID: 24801174
[TBL] [Abstract][Full Text] [Related]
15. Urinary Biomarkers KIM-1 and NGAL for Detection of Chronic Kidney Disease of Uncertain Etiology (CKDu) among Agricultural Communities in Sri Lanka.
De Silva PM; Mohammed Abdul KS; Eakanayake EM; Jayasinghe SS; Jayasumana C; Asanthi HB; Perera HS; Chaminda GG; Chandana EP; Siribaddana SH
PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004979. PubMed ID: 27643785
[TBL] [Abstract][Full Text] [Related]
16. Assessment of kidney function in diabetic patients. Is there a role for new biomarkers NGAL, cystatin C and KIM-1?
Matys U; Bachorzewska-Gajewska H; Malyszko J; Dobrzycki S
Adv Med Sci; 2013; 58(2):353-61. PubMed ID: 24384771
[TBL] [Abstract][Full Text] [Related]
17. Value of urinary KIM-1 and NGAL combined with serum Cys C for predicting acute kidney injury secondary to decompensated cirrhosis.
Lei L; Li LP; Zeng Z; Mu JX; Yang X; Zhou C; Wang ZL; Zhang H
Sci Rep; 2018 May; 8(1):7962. PubMed ID: 29784944
[TBL] [Abstract][Full Text] [Related]
18. Urinary calprotectin, NGAL, and KIM-1 in the differentiation of primarily inflammatory vs. non-inflammatory stable chronic kidney diseases.
Seibert FS; Sitz M; Passfall J; Haesner M; Laschinski P; Buhl M; Bauer F; Rohn B; Babel N; Westhoff TH
Ren Fail; 2021 Dec; 43(1):417-424. PubMed ID: 33663323
[TBL] [Abstract][Full Text] [Related]
19. The Tubular Damage Markers: Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 in Newborns with Intrauterine Growth Restriction.
Kamianowska M; Szczepański M; Kulikowska EE; Bebko B; Wasilewska A
Neonatology; 2019; 115(2):169-174. PubMed ID: 30513528
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Urinary Calprotectin, NGAL and KIM-1 in Chronic Kidney Disease.
Seibert FS; Sitz M; Passfall J; Haesner M; Laschinski P; Buhl M; Bauer F; Babel N; Pagonas N; Westhoff TH
Kidney Blood Press Res; 2018; 43(4):1255-1262. PubMed ID: 30078006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
